Literature DB >> 35726057

Identification of early neurodegenerative pathways in progressive multiple sclerosis.

Max Kaufmann1,2, Anna-Lena Schaupp2, Rosa Sun2,3,4, Fabian Coscia3,5, Calliope A Dendrou2,6, Adrian Cortes2, Gurman Kaur2,7,8, Hayley G Evans2, Annelie Mollbrink9, José Fernández Navarro9, Jana K Sonner1, Christina Mayer1, Gabriele C DeLuca10, Joakim Lundeberg9, Paul M Matthews11,12, Kathrine E Attfield2, Manuel A Friese1, Matthias Mann3,13, Lars Fugger14,15.   

Abstract

Progressive multiple sclerosis (MS) is characterized by unrelenting neurodegeneration, which causes cumulative disability and is refractory to current treatments. Drug development to prevent disease progression is an urgent clinical need yet is constrained by an incomplete understanding of its complex pathogenesis. Using spatial transcriptomics and proteomics on fresh-frozen human MS brain tissue, we identified multicellular mechanisms of progressive MS pathogenesis and traced their origin in relation to spatially distributed stages of neurodegeneration. By resolving ligand-receptor interactions in local microenvironments, we discovered defunct trophic and anti-inflammatory intercellular communications within areas of early neuronal decline. Proteins associated with neuronal damage in patient samples showed mechanistic concordance with published in vivo knockdown and central nervous system (CNS) disease models, supporting their causal role and value as potential therapeutic targets in progressive MS. Our findings provide a new framework for drug development strategies, rooted in an understanding of the complex cellular and signaling dynamics in human diseased tissue that facilitate this debilitating disease.
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.

Entities:  

Mesh:

Year:  2022        PMID: 35726057     DOI: 10.1038/s41593-022-01097-3

Source DB:  PubMed          Journal:  Nat Neurosci        ISSN: 1097-6256            Impact factor:   28.771


  63 in total

1.  A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis.

Authors:  Roberta Magliozzi; Owain W Howell; Cheryl Reeves; Federico Roncaroli; Richard Nicholas; Barbara Serafini; Francesca Aloisi; Richard Reynolds
Journal:  Ann Neurol       Date:  2010-10       Impact factor: 10.422

2.  Visualization and analysis of gene expression in tissue sections by spatial transcriptomics.

Authors:  Patrik L Ståhl; Fredrik Salmén; Sanja Vickovic; Anna Lundmark; José Fernández Navarro; Jens Magnusson; Stefania Giacomello; Michaela Asp; Jakub O Westholm; Mikael Huss; Annelie Mollbrink; Sten Linnarsson; Simone Codeluppi; Åke Borg; Fredrik Pontén; Paul Igor Costea; Pelin Sahlén; Jan Mulder; Olaf Bergmann; Joakim Lundeberg; Jonas Frisén
Journal:  Science       Date:  2016-07-01       Impact factor: 47.728

3.  Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Authors:  Xavier Montalban; Stephen L Hauser; Ludwig Kappos; Douglas L Arnold; Amit Bar-Or; Giancarlo Comi; Jérôme de Seze; Gavin Giovannoni; Hans-Peter Hartung; Bernhard Hemmer; Fred Lublin; Kottil W Rammohan; Krzysztof Selmaj; Anthony Traboulsee; Annette Sauter; Donna Masterman; Paulo Fontoura; Shibeshih Belachew; Hideki Garren; Nicole Mairon; Peter Chin; Jerry S Wolinsky
Journal:  N Engl J Med       Date:  2016-12-21       Impact factor: 91.245

4.  Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.

Authors:  Ludwig Kappos; Amit Bar-Or; Bruce A C Cree; Robert J Fox; Gavin Giovannoni; Ralf Gold; Patrick Vermersch; Douglas L Arnold; Sophie Arnould; Tatiana Scherz; Christian Wolf; Erik Wallström; Frank Dahlke
Journal:  Lancet       Date:  2018-03-23       Impact factor: 79.321

Review 5.  Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives.

Authors:  Daniel Ontaneda; Robert J Fox; Jeremy Chataway
Journal:  Lancet Neurol       Date:  2015-02       Impact factor: 44.182

Review 6.  Immunopathology of multiple sclerosis.

Authors:  Calliope A Dendrou; Lars Fugger; Manuel A Friese
Journal:  Nat Rev Immunol       Date:  2015-08-07       Impact factor: 53.106

7.  The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis.

Authors:  Antonio Scalfari; Chiara Romualdi; Richard S Nicholas; Miriam Mattoscio; Roberta Magliozzi; Aldo Morra; Salvatore Monaco; Paolo A Muraro; Massimiliano Calabrese
Journal:  Neurology       Date:  2018-05-16       Impact factor: 9.910

8.  A streamlined mass spectrometry-based proteomics workflow for large scale FFPE tissue analysis.

Authors:  Fabian Coscia; Sophia Doll; Jacob Mathias Bech; Lisa Schweizer; Andreas Mund; Ernst Lengyel; Jan Lindebjerg; Gunvor Iben Madsen; José M A Moreira; Matthias Mann
Journal:  J Pathol       Date:  2020-03-10       Impact factor: 7.996

Review 9.  Treatment of multiple sclerosis - success from bench to bedside.

Authors:  Mar Tintore; Angela Vidal-Jordana; Jaume Sastre-Garriga
Journal:  Nat Rev Neurol       Date:  2019-01       Impact factor: 42.937

10.  Neocortical neuronal, synaptic, and glial loss in multiple sclerosis.

Authors:  C Wegner; M M Esiri; S A Chance; J Palace; P M Matthews
Journal:  Neurology       Date:  2006-09-26       Impact factor: 9.910

View more
  1 in total

1.  Insights into the molecular pathways of progressive multiple sclerosis.

Authors:  Ian Fyfe
Journal:  Nat Rev Neurol       Date:  2022-08       Impact factor: 44.711

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.